Endostatin prospective patient information

The University of Wisconsin Comprehensive Cancer Center (UWCCC) has been chosen by the National Cancer Institute as one of two sites to conduct the first human tests of endostatin. Endostatin is a promising new cancer treatment that may work by disrupting the growth of blood vessels that nourish tumor cells.

Endostatin was first described by scientists in the laboratory of Judah Folkman at Harvard Medical School, Boston, Mass. Endostatin along with angiostatin are potent anticancer agents in mice. The clinical trial at the UWCCC represents the first use of this agent in humans. Investigators at the UWCCC anticipate that this trial will open in approximately six months.

Patients with solid tumors that are refractory to conventional treatments will be recruited to this trial. Patients with renal cell carcinoma, mesothelioma, breast cancer and melanoma may be particularly well suited for this trial. Patients interested in participation in this trial should e-mail uwccc@biostat.wisc.edu or call the UW Cancer Connect line at 1-800-622-8922. In the Madison, Wis., area patients may call 262-5223.